BRCA1 and Ewing sarcoma: We chose a panel of breast and ovarian cancer cell lines with either BRCA1 wild-type or mutant status, as well as several Ewing’s sarcoma cell lines that are BRCA1 wild-type, but had been shown to be sensitive to PARP inhibitors21 (Supplementary Table S1).